Product image of Malarone (Proguanil Hydrochloride, Atovaquone) supplied by GNH India

Malarone

Active Ingredient:
Proguanil Hydrochloride, Atovaquone
Origin:
EU

Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone/proguanil, the active ingredient in Malarone, is a antimalarial combination presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It treats and prevents malaria infection, including acute uncomplicated Plasmodium falciparum malaria, in travelers and patients at risk.

GNH India supplies Malarone as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Glaxosmithkline Pharma A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Malarone is an antimalarial drug used for both prophylaxis and treatment of malaria infections.

  • Prevention of malaria infection (chemoprophylaxis): provides protective effect for travelers to endemic regions.
  • Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears parasitemia and resolves symptoms.
  • Prevention of malaria in individuals exposed to drug‑resistant strains: reduces risk of infection when resistance to other agents is documented.

How It Works

  • Atovaquone interferes with mitochondrial electron transport in Plasmodium parasites, disrupting ATP synthesis, while proguanil is metabolised to cycloguanil, which inhibits the parasite's dihydrofolate reductase enzyme. The combined actions produce synergistic inhibition of parasite replication, leading to rapid clearance of the infection.

Side Effects

Malarone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: occasional tension‑type headache.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Diarrhoea: loose stools that resolve after a few days.
  • Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

  • Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention.
  • Hepatic enzyme elevation: may indicate liver stress.
  • Hypersensitivity reactions (including anaphylaxis): rare but potentially life‑threatening.
  • Blood dyscrasias (e.g., neutropenia, thrombocytopenia): monitor blood counts if symptoms arise.
  • Severe abdominal pain with fever: could signal serious infection.

Precautions & Warnings

Before prescribing Malarone, clinicians should consider several safety factors.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown safety; weigh maternal benefit against infant risk.
  • Renal impairment: dose adjustment may be required in severe dysfunction.
  • Hepatic impairment: use with caution; monitor liver function tests.
  • Drug resistance: ensure adherence to full course to minimise resistance development.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Malarone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Rifampin: markedly reduces atovaquone plasma concentrations.
  • Cimetidine: may increase atovaquone exposure, raising toxicity risk.
  • Protease inhibitors (e.g., ritonavir): can alter metabolism of both components.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminium or magnesium: decrease atovaquone absorption; separate dosing by at least 2 hours.
  • Warfarin: potential for increased INR; monitor coagulation parameters.
  • Macrolide antibiotics (e.g., erythromycin): may raise proguanil levels; observe for enhanced side effects.

Frequently Asked Questions

Malarone is used both to prevent malaria infection in people traveling to endemic areas and to treat acute uncomplicated malaria caused by Plasmodium falciparum. It provides chemoprophylaxis and therapeutic clearance of the parasite when infection occurs.

Atovaquone blocks mitochondrial electron transport in the malaria parasite, halting ATP production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme. The dual action results in synergistic inhibition of parasite growth and replication.

The specific dose and duration of Malarone therapy are determined by the prescribing clinician based on the indication, patient weight, age, renal and hepatic function, and travel itinerary. Patients should follow the prescriber’s instructions exactly.

Safety of Malarone in pregnancy has not been established, and it should be used only if the potential benefit outweighs the risk. Data on breastfeeding are limited; clinicians should consider possible risks to the infant before prescribing.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone combines atovaquone and proguanil, offering a synergistic effect that is effective against many chloroquine‑resistant strains. Compared with single‑agent therapies such as chloroquine or mefloquine, it often has a more favourable tolerability profile, though cost and availability may differ.

Malarone tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep out of reach of children and avoid storing in humid environments such as bathrooms.

Malarone is taken orally with food or a milky drink to improve absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, taken daily throughout the stay, and continued for 7 days after leaving. For treatment, the full prescribed course is taken as directed.

Serious risks, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations, hypersensitivity reactions including anaphylaxis, and blood‑cell abnormalities like neutropenia. Patients should seek immediate medical care if they develop rash, jaundice, fever, or unexplained bruising.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any tablet components. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in pregnant women unless no safer alternative exists.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Proguanil Hydrochloride, Atovaquone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT